Early (less than seven days following birth) higher showed no clear difference in hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (low certainty).
It is very uncertain whether early (less than seven days following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for all-cause mortality (11 studies, I2=89%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for ACVD-related events (13 studies, I2=75%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
Higher‐dose heparin showed no clear difference in VTE compared with standard‐dose heparin (low certainty).
Higher‐dose heparin showed no clear difference in major bleeding compared with standard‐dose heparin (low certainty).
It is very uncertain whether higher‐dose heparin changes PE compared with standard‐dose heparin (very low certainty).
It is very uncertain whether higher‐dose heparin changes DVT compared with standard‐dose heparin (very low certainty).
It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).